Skip to main content
NCBI home page
The Western Journal of Medicine logoLink to The Western Journal of Medicine
. 1994 Sep;161(3):292–298.

Role of steroids and immunosuppression and effects of interferon beta-1b in multiple sclerosis.

D E Goodkin 1
PMCID: PMC1011412  PMID: 7975569

Abstract

Corticosteroids, corticotropin, azathioprine, cyclophosphamide, and IFN-beta 1b have each had a substantial effect on the care of patients with multiple sclerosis and the design of subsequent clinical trials of experimental therapeutics for MS. The use of MRI scanning and more sensitive clinical outcome measures will possibly enable us to complete clinical trials in a fraction of the time required for earlier trials. The release of Betaseron, which favorably alters the attack rate in ambulatory patients with relapsing-remitting MS has brought a sense of renewed optimism to patients with MS, their families, and their care providers. New promising therapies for chronic progressive MS and biologic products possibly capable of enhancing the effects of IFN-beta 1b in patients with relapsing MS are setting the stage for additional important therapeutic advances in this disease.

Full text

PDF
292

Images in this article

292Image
on p.292

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barkhof F., Hommes O. R., Scheltens P., Valk J. Quantitative MRI changes in gadolinium-DTPA enhancement after high-dose intravenous methylprednisolone in multiple sclerosis. Neurology. 1991 Aug;41(8):1219–1222. doi: 10.1212/wnl.41.8.1219. [DOI] [PubMed] [Google Scholar]
  2. Barnes M. P., Bateman D. E., Cleland P. G., Dick D. J., Walls T. J., Newman P. K., Saunders M., Tilley P. J. Intravenous methylprednisolone for multiple sclerosis in relapse. J Neurol Neurosurg Psychiatry. 1985 Feb;48(2):157–159. doi: 10.1136/jnnp.48.2.157. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Beck R. W., Cleary P. A., Anderson M. M., Jr, Keltner J. L., Shults W. T., Kaufman D. I., Buckley E. G., Corbett J. J., Kupersmith M. J., Miller N. R. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group. N Engl J Med. 1992 Feb 27;326(9):581–588. doi: 10.1056/NEJM199202273260901. [DOI] [PubMed] [Google Scholar]
  4. Beck R. W., Cleary P. A., Trobe J. D., Kaufman D. I., Kupersmith M. J., Paty D. W., Brown C. H. The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. The Optic Neuritis Study Group. N Engl J Med. 1993 Dec 9;329(24):1764–1769. doi: 10.1056/NEJM199312093292403. [DOI] [PubMed] [Google Scholar]
  5. Beck R. W. Corticosteroid treatment of optic neuritis: a need to change treatment practices. The Optic Neuritis Study Group. Neurology. 1992 Jun;42(6):1133–1135. doi: 10.1212/wnl.42.6.1133. [DOI] [PubMed] [Google Scholar]
  6. Bornstein M. B., Miller A., Slagle S., Weitzman M., Crystal H., Drexler E., Keilson M., Merriam A., Wassertheil-Smoller S., Spada V. A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis. N Engl J Med. 1987 Aug 13;317(7):408–414. doi: 10.1056/NEJM198708133170703. [DOI] [PubMed] [Google Scholar]
  7. Cyclophosphamide and plasma exchange in multiple sclerosis. Lancet. 1991 Apr 27;337(8748):1033–1034. [PubMed] [Google Scholar]
  8. Dinarello C. A., Gelfand J. A., Wolff S. M. Anticytokine strategies in the treatment of the systemic inflammatory response syndrome. JAMA. 1993 Apr 14;269(14):1829–1835. [PubMed] [Google Scholar]
  9. Durelli L., Cocito D., Riccio A., Barile C., Bergamasco B., Baggio G. F., Perla F., Delsedime M., Gusmaroli G., Bergamini L. High-dose intravenous methylprednisolone in the treatment of multiple sclerosis: clinical-immunologic correlations. Neurology. 1986 Feb;36(2):238–243. doi: 10.1212/wnl.36.2.238. [DOI] [PubMed] [Google Scholar]
  10. Ebers G. C. Optic neuritis and multiple sclerosis. Arch Neurol. 1985 Jul;42(7):702–704. doi: 10.1001/archneur.1985.04060070096025. [DOI] [PubMed] [Google Scholar]
  11. Ellison G. W., Myers L. W., Mickey M. R., Graves M. C., Tourtellotte W. W., Syndulko K., Holevoet-Howson M. I., Lerner C. D., Frane M. V., Pettler-Jennings P. A placebo-controlled, randomized, double-masked, variable dosage, clinical trial of azathioprine with and without methylprednisolone in multiple sclerosis. Neurology. 1989 Aug;39(8):1018–1026. doi: 10.1212/wnl.39.8.1018. [DOI] [PubMed] [Google Scholar]
  12. Flenniken A. M., Galabru J., Rutherford M. N., Hovanessian A. G., Williams B. R. Expression of interferon-induced genes in different tissues of mice. J Virol. 1988 Sep;62(9):3077–3083. doi: 10.1128/jvi.62.9.3077-3083.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Fog T. The long-term treatment of multiple sclerosis with corticoids. Acta Neurol Scand Suppl. 1965;13(Pt 2):473–484. doi: 10.1111/j.1600-0404.1965.tb01916.x. [DOI] [PubMed] [Google Scholar]
  14. GLASER G. H., RANDT C. T., HOEFER P. F. A., MERRITT H. H., TRAEGER C. H. The influence of adrenocorticotropic hormone (ACTH) on central nervous system and neuromuscular function. Trans Am Neurol Assoc. 1950;51:98–104. [PubMed] [Google Scholar]
  15. Goodkin D. E., Bailly R. C., Teetzen M. L., Hertsgaard D., Beatty W. W. The efficacy of azathioprine in relapsing-remitting multiple sclerosis. Neurology. 1991 Jan;41(1):20–25. doi: 10.1212/wnl.41.1.20. [DOI] [PubMed] [Google Scholar]
  16. Goodkin D. E., Plencner S., Palmer-Saxerud J., Teetzen M., Hertsgaard D. Cyclophosphamide in chronic progressive multiple sclerosis. Maintenance vs nonmaintenance therapy. Arch Neurol. 1987 Aug;44(8):823–827. doi: 10.1001/archneur.1987.00520200027013. [DOI] [PubMed] [Google Scholar]
  17. Goodkin D. E., Ransohoff R. M., Rudick R. A. Experimental therapies for multiple sclerosis: current status. Cleve Clin J Med. 1992 Jan-Feb;59(1):63–74. doi: 10.3949/ccjm.59.1.63. [DOI] [PubMed] [Google Scholar]
  18. Goodkin D. E., Rudick R. A., VanderBrug Medendorp S., Greene T., Schwetz K. M., Fischer J., Daughtry M. M., Ross J., Van Dyke C. Low-dose (7.5 mg) oral methotrexate for chronic progressive multiple sclerosis. Design of a randomized, placebo-controlled trial with sample size benefits from a composite outcome variable including preliminary data on toxicity. Online J Curr Clin Trials. 1992 Sep 25;DOC:[7723 words–paragraphs]. [PubMed] [Google Scholar]
  19. Gould E. S., Bird A. C., Leaver P. K., McDonald W. I. Treatmenf of optic neuritis by retrobulbar injection of triamcinolone. Br Med J. 1977 Jun 11;1(6075):1495–1497. doi: 10.1136/bmj.1.6075.1495. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Hauser S. L., Dawson D. M., Lehrich J. R., Beal M. F., Kevy S. V., Propper R. D., Mills J. A., Weiner H. L. Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH. N Engl J Med. 1983 Jan 27;308(4):173–180. doi: 10.1056/NEJM198301273080401. [DOI] [PubMed] [Google Scholar]
  21. Hofman F. M., von Hanwehr R. I., Dinarello C. A., Mizel S. B., Hinton D., Merrill J. E. Immunoregulatory molecules and IL 2 receptors identified in multiple sclerosis brain. J Immunol. 1986 May 1;136(9):3239–3245. [PubMed] [Google Scholar]
  22. ISAACS A., LINDENMANN J. Virus interference. I. The interferon. Proc R Soc Lond B Biol Sci. 1957 Sep 12;147(927):258–267. doi: 10.1098/rspb.1957.0048. [DOI] [PubMed] [Google Scholar]
  23. Jacobs L., O'Malley J., Freeman A., Ekes R. Intrathecal interferon reduces exacerbations of multiple sclerosis. Science. 1981 Nov 27;214(4524):1026–1028. doi: 10.1126/science.6171035. [DOI] [PubMed] [Google Scholar]
  24. Jacobs L., Salazar A. M., Herndon R., Reese P. A., Freeman A., Jozefowicz R., Cuetter A., Husain F., Smith W. A., Ekes R. Intrathecally administered natural human fibroblast interferon reduces exacerbations of multiple sclerosis. Results of a multicenter, double-blind study. Arch Neurol. 1987 Jun;44(6):589–595. doi: 10.1001/archneur.1987.00520180013008. [DOI] [PubMed] [Google Scholar]
  25. KURTZKE J. F. A new scale for evaluating disability in multiple sclerosis. Neurology. 1955 Aug;5(8):580–583. doi: 10.1212/wnl.5.8.580. [DOI] [PubMed] [Google Scholar]
  26. Kappos L., Patzold U., Dommasch D., Poser S., Haas J., Krauseneck P., Malin J. P., Fierz W., Graffenried B. U., Gugerli U. S. Cyclosporine versus azathioprine in the long-term treatment of multiple sclerosis--results of the German multicenter study. Ann Neurol. 1988 Jan;23(1):56–63. doi: 10.1002/ana.410230110. [DOI] [PubMed] [Google Scholar]
  27. Kinlen L. J. Incidence of cancer in rheumatoid arthritis and other disorders after immunosuppressive treatment. Am J Med. 1985 Jan 21;78(1A):44–49. doi: 10.1016/0002-9343(85)90245-1. [DOI] [PubMed] [Google Scholar]
  28. Kurtzke J. F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983 Nov;33(11):1444–1452. doi: 10.1212/wnl.33.11.1444. [DOI] [PubMed] [Google Scholar]
  29. Lhermitte F., Marteau R., de Saxcé H. Traitement des formes évolutives et graves de sclérose en plaques par l'association sérum antilymphocytaire, azathioprine, prednisone. Résultats cliniques et biologiques. Comparaison avec un groupe témoin traité par azathioprine et prednisone seuls. Surveillance pendant 4 ans. Rev Neurol (Paris) 1987;143(2):98–107. [PubMed] [Google Scholar]
  30. Likosky W. H., Fireman B., Elmore R., Eno G., Gale K., Goode G. B., Ikeda K., Laster J., Mosher C., Rozance J. Intense immunosuppression in chronic progressive multiple sclerosis: the Kaiser study. J Neurol Neurosurg Psychiatry. 1991 Dec;54(12):1055–1060. doi: 10.1136/jnnp.54.12.1055. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. MILLER H., NEWELL D. J., RIDLEY A. Multiple sclerosis. Treatment of acute exacerbations with corticotrophin (A.C.T.H.). Lancet. 1961 Nov 18;2(7212):1120–1122. doi: 10.1016/s0140-6736(61)91030-3. [DOI] [PubMed] [Google Scholar]
  32. Merigan T. C., Rand K. H., Pollard R. B., Abdallah P. S., Jordan G. W., Fried R. P. Human leukocyte interferon for the treatment of herpes zoster in patients with cancer. N Engl J Med. 1978 May 4;298(18):981–987. doi: 10.1056/NEJM197805042981801. [DOI] [PubMed] [Google Scholar]
  33. Mertin J., Rudge P., Kremer M., Healey M. J., Knight S. C., Compston A., Batchelor J. R., Thompson E. J., Halliday A. M., Denman M. Double-blind controlled trial of immunosuppression in the treatment of multiple sclerosis: final report. Lancet. 1982 Aug 14;2(8294):351–354. doi: 10.1016/s0140-6736(82)90547-5. [DOI] [PubMed] [Google Scholar]
  34. Milanese C., La Mantia L., Salmaggi A., Campi A., Bortolami C., Tajoli L., Nespolo A., Corridori F. Double blind controlled randomized study on azathioprine efficacy in multiple sclerosis. Preliminary results. Ital J Neurol Sci. 1988 Feb;9(1):53–57. doi: 10.1007/BF02334408. [DOI] [PubMed] [Google Scholar]
  35. Millar J. H., Vas C. J., Noronha M. J., Liversedge L. A., Rawson M. D. Long-term treatment of multiple sclerosis with corticotrophin. Lancet. 1967 Aug 26;2(7513):429–431. doi: 10.1016/s0140-6736(67)90850-1. [DOI] [PubMed] [Google Scholar]
  36. Miller D. H., McDonald W. I., Blumhardt L. D., du Boulay G. H., Halliday A. M., Johnson G., Kendall B. E., Kingsley D. P., MacManus D. G., Moseley I. F. Magnetic resonance imaging in isolated noncompressive spinal cord syndromes. Ann Neurol. 1987 Dec;22(6):714–723. doi: 10.1002/ana.410220607. [DOI] [PubMed] [Google Scholar]
  37. Miller D. H., Ormerod I. E., Rudge P., Kendall B. E., Moseley I. F., McDonald W. I. The early risk of multiple sclerosis following isolated acute syndromes of the brainstem and spinal cord. Ann Neurol. 1989 Nov;26(5):635–639. doi: 10.1002/ana.410260508. [DOI] [PubMed] [Google Scholar]
  38. Milligan N. M., Newcombe R., Compston D. A. A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: 1. Clinical effects. J Neurol Neurosurg Psychiatry. 1987 May;50(5):511–516. doi: 10.1136/jnnp.50.5.511. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Moody D. J., Fahey J. L., Grable E., Ellison G. W., Myers L. W. Administration of monthly pulses of cyclophosphamide in multiple sclerosis patients. Delayed recovery of several immune parameters following discontinuation of long-term cyclophosphamide treatment. J Neuroimmunol. 1987 Mar;14(2):175–182. doi: 10.1016/0165-5728(87)90051-8. [DOI] [PubMed] [Google Scholar]
  40. Moody D. J., Kagan J., Liao D., Ellison G. W., Myers L. W. Administration of monthly-pulse cyclophosphamide in multiple sclerosis patients. Effects of long-term treatment on immunologic parameters. J Neuroimmunol. 1987 Mar;14(2):161–173. doi: 10.1016/0165-5728(87)90050-6. [DOI] [PubMed] [Google Scholar]
  41. Morimoto C., Hafler D. A., Weiner H. L., Letvin N. L., Hagan M., Daley J., Schlossman S. F. Selective loss of the suppressor-inducer T-cell subset in progressive multiple sclerosis. Analysis with anti-2H4 monoclonal antibody. N Engl J Med. 1987 Jan 8;316(2):67–72. doi: 10.1056/NEJM198701083160202. [DOI] [PubMed] [Google Scholar]
  42. Neighbour P. A., Bloom B. R. Absence of virus-induced lymphocyte suppression and interferon production in multiple sclerosis. Proc Natl Acad Sci U S A. 1979 Jan;76(1):476–480. doi: 10.1073/pnas.76.1.476. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Noseworthy J. H., Ebers G. C., Vandervoort M. K., Farquhar R. E., Yetisir E., Roberts R. The impact of blinding on the results of a randomized, placebo-controlled multiple sclerosis clinical trial. Neurology. 1994 Jan;44(1):16–20. doi: 10.1212/wnl.44.1.16. [DOI] [PubMed] [Google Scholar]
  44. Noseworthy J. H., Vandervoort M. K., Penman M., Ebers G., Shumak K., Seland T. P., Roberts R., Yetisir E., Gent M., Taylor D. W. Cyclophosphamide and plasma exchange in multiple sclerosis. Lancet. 1991 Jun 22;337(8756):1540–1541. doi: 10.1016/0140-6736(91)93226-y. [DOI] [PubMed] [Google Scholar]
  45. Panitch H. S., Hirsch R. L., Schindler J., Johnson K. P. Treatment of multiple sclerosis with gamma interferon: exacerbations associated with activation of the immune system. Neurology. 1987 Jul;37(7):1097–1102. doi: 10.1212/wnl.37.7.1097. [DOI] [PubMed] [Google Scholar]
  46. Paty D. W., Li D. K. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group. Neurology. 1993 Apr;43(4):662–667. doi: 10.1212/wnl.43.4.662. [DOI] [PubMed] [Google Scholar]
  47. Poser C. M., Paty D. W., Scheinberg L., McDonald W. I., Davis F. A., Ebers G. C., Johnson K. P., Sibley W. A., Silberberg D. H., Tourtellotte W. W. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol. 1983 Mar;13(3):227–231. doi: 10.1002/ana.410130302. [DOI] [PubMed] [Google Scholar]
  48. Rawson M. D., Liversedge L. A., Goldfarb G. Treatment of acute retrobulbar neuritis with corticotrophin. Lancet. 1966 Nov 12;2(7472):1044–1046. doi: 10.1016/s0140-6736(66)92025-3. [DOI] [PubMed] [Google Scholar]
  49. Rawson M. D., Liversedge L. A. Treatment of retrobulbar neuritis with corticotrophin. Lancet. 1969 Jul 26;2(7613):222–222. doi: 10.1016/s0140-6736(69)91469-x. [DOI] [PubMed] [Google Scholar]
  50. Rose A. S., Kuzma J. W., Kurtzke J. F., Namerow N. S., Sibley W. A., Tourtellotte W. W. Cooperative study in the evaluation of therapy in multiple sclerosis. ACTH vs. placebo--final report. Neurology. 1970 May;20(5):1–59. doi: 10.1212/wnl.20.5_part_2.1. [DOI] [PubMed] [Google Scholar]
  51. SCHUMACHER G. A., BEEBE G., KIBLER R. F., KURLAND L. T., KURTZKE J. F., MCDOWELL F., NAGLER B., SIBLEY W. A., TOURTELLOTTE W. W., WILLMON T. L. PROBLEMS OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS: REPORT BY THE PANEL ON THE EVALUATION OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS. Ann N Y Acad Sci. 1965 Mar 31;122:552–568. doi: 10.1111/j.1749-6632.1965.tb20235.x. [DOI] [PubMed] [Google Scholar]
  52. Seboun E., Robinson M. A., Doolittle T. H., Ciulla T. A., Kindt T. J., Hauser S. L. A susceptibility locus for multiple sclerosis is linked to the T cell receptor beta chain complex. Cell. 1989 Jun 30;57(7):1095–1100. doi: 10.1016/0092-8674(89)90046-9. [DOI] [PubMed] [Google Scholar]
  53. Selky A. K., Dobyns W. B., Yee R. D. Idiopathic intracranial hypertension and facial diplegia. Neurology. 1994 Feb;44(2):357–357. doi: 10.1212/wnl.44.2.357. [DOI] [PubMed] [Google Scholar]
  54. Selky A. K., Dobyns W. B., Yee R. D. Idiopathic intracranial hypertension and facial diplegia. Neurology. 1994 Feb;44(2):357–357. doi: 10.1212/wnl.44.2.357. [DOI] [PubMed] [Google Scholar]
  55. Silberberg D. H. Corticosteroids and optic neuritis. N Engl J Med. 1993 Dec 9;329(24):1808–1810. doi: 10.1056/NEJM199312093292411. [DOI] [PubMed] [Google Scholar]
  56. Smith M. E., Stone L. A., Albert P. S., Frank J. A., Martin R., Armstrong M., Maloni H., McFarlin D. E., McFarland H. F. Clinical worsening in multiple sclerosis is associated with increased frequency and area of gadopentetate dimeglumine-enhancing magnetic resonance imaging lesions. Ann Neurol. 1993 May;33(5):480–489. doi: 10.1002/ana.410330511. [DOI] [PubMed] [Google Scholar]
  57. Smith T., Zeeberg I., Sjö O. Evoked potentials in multiple sclerosis before and after high-dose methylprednisolone infusion. Eur Neurol. 1986;25(1):67–73. doi: 10.1159/000115989. [DOI] [PubMed] [Google Scholar]
  58. Stiehm E. R., Kronenberg L. H., Rosenblatt H. M., Bryson Y., Merigan T. C. UCLA conference. Interferon: immunobiology and clinical significance. Ann Intern Med. 1982 Jan;96(1):80–93. doi: 10.7326/0003-4819-96-1-80. [DOI] [PubMed] [Google Scholar]
  59. Swinburn W. R., Liversedge L. A. Long-term treatment of multiple sclerosis with azathioprine. J Neurol Neurosurg Psychiatry. 1973 Feb;36(1):124–126. doi: 10.1136/jnnp.36.1.124. [DOI] [PMC free article] [PubMed] [Google Scholar]
  60. Thompson A. J., Kennard C., Swash M., Summers B., Yuill G. M., Shepherd D. I., Roche S., Perkin G. D., Loizou L. A., Ferner R. Relative efficacy of intravenous methylprednisolone and ACTH in the treatment of acute relapse in MS. Neurology. 1989 Jul;39(7):969–971. doi: 10.1212/wnl.39.7.969. [DOI] [PubMed] [Google Scholar]
  61. Troiano R. A., Hafstein M. P., Zito G., Ruderman M. I., Dowling P. C., Cook S. D. The effect of oral corticosteroid dosage on CT enhancing multiple sclerosis plaques. J Neurol Sci. 1985 Aug;70(1):67–72. doi: 10.1016/0022-510x(85)90188-1. [DOI] [PubMed] [Google Scholar]
  62. Troiano R., Cook S. D., Dowling P. C. Steroid therapy in multiple sclerosis. Point of view. Arch Neurol. 1987 Aug;44(8):803–807. doi: 10.1001/archneur.1987.00520200007008. [DOI] [PubMed] [Google Scholar]
  63. Troiano R., Hafstein M., Ruderman M., Dowling P., Cook S. Effect of high-dose intravenous steroid administration on contrast-enhancing computed tomographic scan lesions in multiple sclerosis. Ann Neurol. 1984 Mar;15(3):257–263. doi: 10.1002/ana.410150309. [DOI] [PubMed] [Google Scholar]
  64. Trotter J. L., Garvey W. F. Prolonged effects of large-dose methylprednisolone infusion in multiple sclerosis. Neurology. 1980 Jul;30(7 Pt 1):702–708. doi: 10.1212/wnl.30.7.702. [DOI] [PubMed] [Google Scholar]
  65. Tucker W. G., Kapphahn K. H. A preliminary evaluation of azathioprine (Imuran) in the treatment of multiple sclerosis. Henry Ford Hosp Med J. 1969 Summer;17(2):89–92. [PubMed] [Google Scholar]
  66. Uitdehaag B. M., Nillesen W. M., Hommes O. R. Long-lasting effects of cyclophosphamide on lymphocytes in peripheral blood and spinal fluid. Acta Neurol Scand. 1989 Jan;79(1):12–17. doi: 10.1111/j.1600-0404.1989.tb03702.x. [DOI] [PubMed] [Google Scholar]
  67. Weiner H. L., Mackin G. A., Orav E. J., Hafler D. A., Dawson D. M., LaPierre Y., Herndon R., Lehrich J. R., Hauser S. L., Turel A. Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: final report of the Northeast Cooperative Multiple Sclerosis Treatment Group. Neurology. 1993 May;43(5):910–918. doi: 10.1212/wnl.43.5.910. [DOI] [PubMed] [Google Scholar]
  68. Wong G. H., Bartlett P. F., Clark-Lewis I., Battye F., Schrader J. W. Inducible expression of H-2 and Ia antigens on brain cells. Nature. 1984 Aug 23;310(5979):688–691. doi: 10.1038/310688a0. [DOI] [PubMed] [Google Scholar]
  69. Yudkin P. L., Ellison G. W., Ghezzi A., Goodkin D. E., Hughes R. A., McPherson K., Mertin J., Milanese C. Overview of azathioprine treatment in multiple sclerosis. Lancet. 1991 Oct 26;338(8774):1051–1055. doi: 10.1016/0140-6736(91)91909-e. [DOI] [PubMed] [Google Scholar]

Articles from Western Journal of Medicine are provided here courtesy of BMJ Publishing Group

RESOURCES